Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B

Clinical Pharmacokinetics

Volumn 54, Issue 2, 2015, Pages 133-146

  Geary, Richard S ^a   Baker, Brenda F ^a   Crooke, Stanley T ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MIPOMERSEN; ANTISENSE OLIGODEOXYNUCLEOTIDE; APOLIPOPROTEIN B; HYPOCHOLESTEROLEMIC AGENT; OLIGONUCLEOTIDE;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG METABOLISM; DRUG SCREENING; DRUG SYNTHESIS; ELIMINATION HALF-LIFE; ENDOCYTOSIS; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL (TOPIC); HYPERLIPOPROTEINEMIA TYPE I; METABOLISM; NUCLEOTIDE SEQUENCE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; BASE SEQUENCE; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERLIPOPROTEINEMIA TYPE I; MODELS, MOLECULAR; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDES;

EID: 84925541081     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0224-4     Document Type: Review

References (49)

1. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259–93.
2. Crooke ST, Vickers T, Lima W, et al. Mechanisms of antisense drug action, an introduction. In: Crooke ST, editor. Antisense drug technology: principles, strategies, and applications. 2nd ed. Boca Raton: CRC Press; 2007. p. 3–46.
3. Wu H, Lima WF, Zhang H, et al. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem. 2004;279:17181–9.
4. Zhang H, Cook J, Nickel J, et al. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol. 2000;18:862–7.
5. Yu RZ, Lemonidis KM, Graham MJ, et al. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol. 2009;77:910–9.
6. Moser Altmann KH, Dean NM, Fabbro D, et al. Second generation of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals. Chimia. 1996;50:168–76.
7. Davis RA. Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim Biophys Acta. 1999;1440:1–31.
8. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60:2631–9.
9. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307:1302–9.
10. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.
11. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39.
12. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:133–40.
13. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223:262–8.
14. Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011;124:2202–7.
15. Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014;129:1022–32.
16. Brown WV, Rader DJ, Goldberg AC. JCL roundtable: drug treatment of severe forms of familial hypercholesterolemia. J Clin Lipidol. 2014;8:10–7.
17. ® (mipomersen sodium) injection prescribing information. 2013. Available from: http://www.kynamro.com/~/media/Kynamro/Files/KYNAMRO-PI.pdf. Accessed 6 Jun 2014.
18. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998–1006.
19. Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337–45.
20. Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease. J Am Coll Cardiol. 2012;60:716–21.
21. Kraft HG, Lingenhel A, Raal FJ, Hohenegger M, Utermann G. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000;20:522–8.
22. Levin AA, Yu RZ, Geary RS. Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. In: Crooke ST, editor. Antisense drug technology: principles, strategies, and applications. 2nd ed. Boca Raton: CRC Press; 2007. p. 183–216.
23. Geary RS, Yu RZ, Siwkowski A, et al. Pharmacokinetic/pharmacodynamic properties of phosphorothioate 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides in animal and man. In: Crooke ST, editor. Antisense drug technology: principles, strategies, and applications. 2nd ed. Boca Raton: CRC Press; 2007. p. 305–26.
24. Geary RS. Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2009;5:381–91.
25. Yu RZ, Grundy JS, Geary RS. Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol. 2013;9:169–82.
26. Crooke ST, Geary RS. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol. 2013;76:269–76.
27. Yu RZ, Kim TW, Hong A, et al. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos. 2007;35(3):460–8.
28. Baek M, Yu RZ, Gaus H, Grundy JS, Geary RS. In vitro metabolic stabilities and metabolism of 2′-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in reincubated rat or human whole liver homogenates. Oligonucleotides. 2010;20:309–16.
29. Yu RZ, Geary RS, Flaim JD, et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2′-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet. 2009;48:39–50.
30. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 2006;114:1729–35.
31. Flaim JD, Grundy JS, Baker BF, et al. Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers. J Am Heart Assoc. 2014;3:e000560.
32. Li Z, Hard ML, Andersen G, et al. Pharmacokinetics, safety and tolerability of mipomersen in healthy Japanese volunteers and comparison with Western subjects. Int J Clin Pharmacol Ther. 2014;52:314–20.
33. Akdim F, Tribble DL, Flaim JD, et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J. 2011;32:2650–9.
34. Akdim F, Stroes ES, Sijbrands EJ, et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol. 2010;55:1611–8.
35. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010;105:1413–9.
36. McGowan MP, Tardif JC, Ceska R, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One. 2012;7:e49006.
37. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012;126:2283–92.
38. Thomas GS, Cromwell WC, Ali S, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013;62:2178–84.
39. Graham MJ, Lee RG, Bell TA 3rd, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112:1479–90.
40. Jones NR, Pegues MA, McCrory MA, Singleton W, Bethune C, Baker BF, Norris DA, Crooke RM, Graham MJ, Szalai AJ. A selective inhibitor of human C-reactive protein translation is efficacious in vitro and in C-reactive protein transgenic mice and humans. Mol Ther Nucleic Acids. 2012;1:e52. doi:10.1038/mtna.2012.44.
41. Santos RD, Duell PB, East C, et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J. Epub 23 Dec 2013.
42. Li Z, Hard ML, Grundy JS, et al. Lack of clinical pharmacodynamic and pharmacokinetic drug-drug interactions between warfarin and the antisense oligonucleotide mipomersen. J Cardiovasc Pharmacol. 2014;64:164–71.
43. Li Z, Yu R, Hard M, et al. The second generation antisense oligonucleotide (ASO) mipomersen does not prolong QT interval in a thorough QT/QTC study in healthy subjects. Clin Pharm Ther. 2014;95:S23.
44. Crooke RM, Graham MJ, Lemonidis KM, et al. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res. 2005;46:872–84.
45. Crooke RM, Baker BF, Wedel MK. Cardiovascular therapeutic applications. In: Crooke ST, editor. Antisense drug technology principles, strategies, and applications. 2nd ed. Boca Raton: CRC Press; 2007. p. 601–39.
46. Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012;33:1142–9.
47. Duell PB, Rose JE, Selvey S, et al. Long term efficacy and safety of mipomersen during 4 years of treatment in a cohort of patients with heterozygous familial hypercholesterolemia and coronary artery disease (CAD). J Clin Lipidology. 2013;7:276.
48. Selvey S, Raal FJ. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces LDL-C in HoFH pediatric patients. J Clin Lipidol. 2014;8:330.
49. Yu R, Geary R, Kim T, Levin AA. Mouse and monkey toxicokinetics of a second generation antisense oligonucleotide (ASO) targeting human apoB-100, following chronic treatment for up to 1 year [abstract no. T2492]. In: Annual Meeting of American Association of Pharmaceutical Scientists; 11–15 November 2007; San Diego (CA).